Pros | ![]() Among most bought funds within the category. | ![]() 5Y returns in the top 25% of the category. ![]() 3Y returns in the top 25% of the category. ![]() Among most bought funds within the category. | ||
Cons | - | - |
INDMoney rank | - | 3/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 1 Years | 7 Years | ||
Fund Size | 1936 Cr | 6104 Cr | ||
Min Investment | SIP ₹100 Lumpsum ₹100 | SIP ₹100 Lumpsum ₹5000 | ||
Expense Ratio | 0.87% | 1.04% | ||
Exit Load | 1% | 1% | ||
Benchmark Index | BSE Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 31 | 39 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (10.97%) Divi's Laboratories Ltd (8.81%) Glenmark Pharmaceuticals Ltd (7.42%) Cipla Ltd (6.33%) Lupin Ltd (5.98%) | Sun Pharmaceuticals Industries Ltd (11.69%) Dr Reddy's Laboratories Ltd (8.85%) Divi's Laboratories Ltd (8.13%) Cipla Ltd (7.54%) Aurobindo Pharma Ltd (5.71%) | ||
No of Sectors | 2 | 3 | ||
Top 3 Sectors | Health (97.68%) Basic Materials (2.32%) | Health (96.53%) Basic Materials (2.35%) Financial Services (1.11%) | ||
Equity % | 98.2% | 95.89% | ||
Debt % | - | - | ||
P/E | 44.94 | 32.47 | ||
P/B | 6.81 | 4.4 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | -4.42% | -4.24% | ||
3-Month Return | 5.4% | 2.47% | ||
6-Month Return | 17.57% | 17.71% | ||
1-Year Return | 11.3% | 5.92% | ||
3-Year Return | - | 29.31% | ||
5-Year Return | - | 21.8% |
Sharpe | - | - | ||
Alpha | - | 3.95 | ||
Beta | - | 0.94 | ||
Standard Deviation | - | 15.52 | ||
Information Ratio | - | 1.17 |
Description | HDFC Pharma and Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Dhruv Muchhal,Nikhil Mathur | Dharmesh Kakkad,Sharmila D’mello |